Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecca Lyon

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Mycologia|May 30, 2014
PCR amplification of SNP loci from crude DNA for large-scale genotyping of oomycetesJian Hu, Rebecca Lyon, Yuxin Zhou, et al.
Plos One|June 1, 2023
A comparison of transporter gene expression in three species of Peronospora plant pathogens during host infectionEric T Johnson, Rebecca Lyon, David Zaitlin, et al.
Plos One|February 2, 2016
Population Structure of Peronospora effusa in the Southwestern United StatesRebecca Lyon, James Correll, Chunda Feng, et al.
Nursing Management (Harrow, London, England : 1994)|November 26, 2025
Implementing and evaluating a development pathway for early-career research nursesArun Vamadevan, Rebecca Lyon, Styja Varghese, et al.
Phytopathology|March 14, 2025
Identification of Novel Basil Downy Mildew Resistance Genes Using <i>De Novo</i> Comparative TranscriptomicsKelly S Allen, Gregory A DeIulio, Robert Pyne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 10, 2022
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 InfectionRichard FitzGerald, Laura Dickinson, Laura Else, et al.
The Journal of Antimicrobial Chemotherapy|June 16, 2026
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infectionSaye H Khoo, Richard FitzGerald, Christopher J Edwards, et al.
Clinical Pharmacology and Therapeutics|March 18, 2026
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib StudyTim Rowland, Richard FitzGerald, Elizabeth Challenger, et al.
Clinical Pharmacology and Therapeutics|October 26, 2021
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, et al.
The Lancet. Infectious Diseases|October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trialSaye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Mycologia|May 30, 2014
PCR amplification of SNP loci from crude DNA for large-scale genotyping of oomycetesJian Hu, Rebecca Lyon, Yuxin Zhou, et al.
Plos One|June 1, 2023
A comparison of transporter gene expression in three species of Peronospora plant pathogens during host infectionEric T Johnson, Rebecca Lyon, David Zaitlin, et al.
Plos One|February 2, 2016
Population Structure of Peronospora effusa in the Southwestern United StatesRebecca Lyon, James Correll, Chunda Feng, et al.
Nursing Management (Harrow, London, England : 1994)|November 26, 2025
Implementing and evaluating a development pathway for early-career research nursesArun Vamadevan, Rebecca Lyon, Styja Varghese, et al.
Phytopathology|March 14, 2025
Identification of Novel Basil Downy Mildew Resistance Genes Using <i>De Novo</i> Comparative TranscriptomicsKelly S Allen, Gregory A DeIulio, Robert Pyne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 10, 2022
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 InfectionRichard FitzGerald, Laura Dickinson, Laura Else, et al.
The Journal of Antimicrobial Chemotherapy|June 16, 2026
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infectionSaye H Khoo, Richard FitzGerald, Christopher J Edwards, et al.
Clinical Pharmacology and Therapeutics|March 18, 2026
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib StudyTim Rowland, Richard FitzGerald, Elizabeth Challenger, et al.
Clinical Pharmacology and Therapeutics|October 26, 2021
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, et al.
The Lancet. Infectious Diseases|October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trialSaye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
Pageof 2